Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 384 clinical trials
None
DAHANCA 30: A Randomized Non-inferiority Trial of Hypoxia-profile Guided Hypoxic Modification of Radiotherapy of HNSCC.

Hypoxic modification of radiotherapy with nimorazole has previously been shown to increase radiosensitivity in hypoxic head and neck squamous cell carcinomas (HNSCC). In Denmark

neck cancer
head and neck cancer
nimorazole
squamous cell carcinoma
cancer
  • 2 views
  • 18 Apr, 2021
  • 1 location
None
Assessment of Efficacy and Safety of Monalizumab Plus Cetuximab Compared to Placebo Plus Cetuximab in Recurrent or Metastatic Head and Neck Cancer

This is a randomized, double-blind, multicenter, global Phase 3 study to assess the efficacy and safety of monalizumab and cetuximab, compared to placebo and cetuximab, in patients with recurrent or metastatic head and neck cancer.

  • 0 views
  • 03 Oct, 2021
  • 170 locations
None
Resource Sparing Curative Radiotherapy for Locally Advanced Squamous Cell Cancer of the Head and Neck: The HYPNO Trial

The aim of the study is to test whether a resource-sparing 4-week, 20-fraction course of accelerated hypofractionated radiotherapy is non-inferior to accelerated radiotherapy delivering 33 fractions over 5.5 weeks in the treatment of patients with Stage I-IV squamous cell carcinoma of the pharynx, larynx and oral cavity with the exception …

caries
head and neck cancer
squamous cell carcinoma
cancer
cancer of the head
  • 15 views
  • 23 Jan, 2021
  • 2 locations
None
A Study of Pembrolizumab (MK-3475) With or Without Lenvatinib (E7080/MK-7902) as First Line (1L) Intervention in a Programmed Cell Death-ligand 1 (PD-L1) Selected Population With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC) (LEAP-010) (MK-7902-010)

head and neck squamous cell carcinoma. Hypotheses include: Pembrolizumab + lenvatinib is superior to pembrolizumab + placebo with respect to Objective Response Rate (ORR) per

caries
measurable disease
mk-3475
squamous cell carcinoma
pembrolizumab
  • 15 views
  • 18 Oct, 2021
  • 151 locations
None
Multicentric Comparative Study Between a Conventional and an Intensive Follow up Strategy After Treatment of a Head and Neck Squamous Cell Carcinoma

than 35 year, in complete remission 2-4 months after treatment of head and neck squamous cell carcinoma Patients will be randomized after the post-treatment check-up (clinical examination and reference

squamous cell carcinoma
cancer
  • 0 views
  • 23 Jan, 2021
None
Combination Study With Soluble LAG-3 Fusion Protein Eftilagimod Alpha (IMP321) and Pembrolizumab in Patients With Previously Untreated Unresectable or Metastatic NSCLC or Recurrent PD-X Refractory NSCLC or With Recurrent or Metastatic HNSCC

Evaluate the safety and efficacy of the combination of eftilagimod alpha with pembrolizumab in non-small cell lung carcinoma and head and neck carcinoma patients.

caries
systemic therapy
EGFR
carcinoma
pembrolizumab
  • 20 views
  • 18 Oct, 2021
  • 19 locations
None
A Study of Pembrolizumab (MK-3475) Plus Carboplatin and Paclitaxel as First-line Treatment of Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma (MK-3475-B10/KEYNOTE B10)

neck squamous cell carcinoma (R/M HNSCC). No statistical hypothesis will be tested in this study.

paclitaxel
carboplatin
mk-3475
carcinoma
squamous cell carcinoma
  • 2 views
  • 18 Oct, 2021
  • 32 locations
None
Enoblituzumab Plus Retifanlimab or Tebotelimab in Head and Neck Cancer

This is a Phase 2 study of enoblituzumab combined with either retifanlimab or tebotelimab administered as first-line treatment to patients with recurrent or metastatic squamous cell carcinoma of

primary tumor
metastatic squamous cell carcinoma
oropharyngeal
measurable disease
carcinoma of oropharynx
  • 1 views
  • 18 Oct, 2021
  • 18 locations
None
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors

A prospective, open-label, multi-cohort, non-randomized, multicenter Phase 2 study evaluating adoptive cell therapy (ACT) with TIL LN-144 (Lifileucel)/LN-145 in combination with checkpoint inhibitors or TIL LN-144 (Lifileucel)/LN-145/LN-145-S1 as a single agent therapy.

systemic therapy
solid tumour
EGFR
measurable disease
carcinoma
  • 123 views
  • 16 Jul, 2021
  • 45 locations
None
A Trial Evaluating the Addition of Nivolumab to Cisplatin-RT for Treatment of Cancers of the Head and Neck

The purpose of this study is to determine the efficacy of nivolumab + cisplatin-RT relative to standard of care (SOC) cisplatin-RT alone, using the disease-free survival (DFS by investigator imaging assessment) as primary endpoint )

neutrophil count
EGFR
cancer
carcinoma
squamous cell carcinoma
  • 5 views
  • 24 Feb, 2021
  • 1 location